Efaproxyn™ the first synthetic small molecule designed to sensitize hypoxic, or oxygen deprived, areas of tumors during radiation therapy by facilitating the release of oxygen from hemoglobin, the oxygen-carrying protein contained within red blood cells, and increasing the level of oxygen in tumors. Currently in Phase III trials.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment